Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review

Cancer Treatment Reviews

Volumn 39, Issue 3, 2013, Pages 241-251

  Bixby, Dale L ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Adherence; Adverse events; Case study; Chronic myeloid leukemia; Drug resistance; Suboptimal response; Tyrosine kinase inhibitor

Indexed keywords

DASATINIB; DICYCLOVERINE; IMATINIB; NILOTINIB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG HYPERSENSITIVITY; FOLLOW UP; GENE MUTATION; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT EDUCATION; PRACTICE GUIDELINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MEDICATION ADHERENCE; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873991298     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.04.010     Document Type: Review

References (98)

1. National Cancer Institute. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. <>; 2011 [accessed 20.12.2011]. http://www.seer.cancer.gov/statfacts/html/cmyl.html.
2. Faderl S., Talpaz M., Estrov Z., Kantarjian H.M. Chronic myelogenous leukemia: biology and therapy. Ann Int Med 1999, 131(3):207-219.
3. National Cancer Institute. Chronic Myelogenous Leukemia Treatment (PDQ). >; 2011 [accessed 07.03.2011]. http://www.cancer.gov/cancertopics/pdq/treatment/CML/healthprofessional/allpages.
4. Nowell P.C., Hungerford D.A. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960, 25:85-109.
5. Rowley J.D. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405):290-293.
6. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 BCR/ABL-transduced bone marrow. Blood 1998, 92(10):3780-3792.
7. Hazlehurst L.A., Bewry N.N., Nair R.R., Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009, 16(2):100-107.
8. Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G. Structural organization of the BCR gene and its role in the Ph[prime] translocation. Nature 1985, 315(6022):758-761.
9. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2.2012. © 2011 National Comprehensive Cancer Network, Inc.. <>; 2011 [accessed 1.12.2011]. http://www.NCCN.org.
10. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
11. American Cancer Society Cancer facts & figures 2011 2011, American Cancer Society, Atlanta.
12. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
13. O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., Radich J.P., et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). ASH Annual Meeting Abstr 2008, 112(11):186.
14. Deininger M., O'Brien S.G., Guilhot F., Goldman J.M., Hochhaus A., Hughes T.P., et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstr 2009, 114(22):1126.
15. de Lavallade H., Apperley J.F., Khorashad J.S., Milojkovic D., Reid A.G., Bua M., et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26(20):3358-3363.
16. Cortes J., Hochhaus A., Hughes T., Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011, 29(5):524-531.
17. Kantarjian H.M., Baccarani M., Jabbour E., Saglio G., Cortes J.E. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011, 17(7):1674-1683.
18. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24):2260-2270.
19. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24):2251-2259.
20. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2011.
21. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; October 2011.
22. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2011;Dec 9 [Epub ahead of print].
23. Kantarjian H.M., Hochhaus A., Saglio G., Souza C.D., Flinn I.W., Stenke L., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12(9):841-851.
24. Baccarani M., Castagnetti F., Gugliotta G., Palandri F., Soverini S. Response definitions and European LeukemiaNet Management Recommendations. Best Pract Res Clin Haematol 2009, 22(3):331-341.
25. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Branford S., Kim D.-W., et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28(3):424-430.
26. Cortes J.E., Kantarjian H.M., Goldberg S.L., Powell B.L., Giles F.J., Wetzler M., et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009, 27(28):4754-4759.
27. Jabbour E., Kantarjian H.M., O'Brien S., Shan J., Quintás-Cardama A., Garcia-Manero G., et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?. J Clin Oncol 2011, 29(32):4260-4265.
28. ClinicalTrials.gov. NCT00802841. Suboptimal study comparing nilotinib and imatinib (LASOR). ; 2011 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00802841?term=nct00802841&rank=1.
29. ClinicalTrials.gov. NCT01043874. Study to evaluate nilotinib in chronic myelogenous leukemia (CML) patients with suboptimal response (SENSOR) <>; 2011 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT01043874?term=nct01043874&rank=1.
30. ClinicalTrials.gov. NCT01400074. Efficacy of nilotinib versus imatinib in Ph+ CML in early CP who have a suboptimal molecular response to imatinib (RE-NICE). <>; 2011 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT01400074?term=nct01400074&rank=1.
31. ClinicalTrials.gov. NCT00644878. Study of molecular response in adult patients on nilotinib with Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) in chronic phase and a suboptimal molecular response to imatinib. <>; 2011 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00644878?term=nct00644878&rank=1.
32. ClinicalTrials.gov. NCT00718263. Efficacy and safety of nilotinib patients with newly diagnosed CML - CP (chronic myelogenous leukemia - chronic phase. <>; 2008 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00718263?term=nct00718263&rank=1.
33. ClinicalTrials.gov. NCT00854841. The randomized study of dasatinib and high-dose imatinib (600mg) in suboptimal responder. <>; 2009 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00854841?term=nct00854841&rank=1.
34. ClinicalTrials.gov. NCT01218477. Dasatinib combo with SMO inhibitor (BMS-833923). <>; 2010 [accessed 1.12.2011]. http://www.clinicaltrials.gov/ct2/show/NCT01218477?term=nct01218477&rank=1
35. Ailawadhi S., Miller C.B., Jillella A.P., Koshy N., Tudor B., Akard L.P., et al. Effect of nilotinib (NIL) on molecular response in chronic myelogenous leukemia - chronic phase (CML-CP) patients (pts) with a suboptimal molecular response to imatinib (IM)-ENABL study update. ASH Annual Meeting Abstr 2011, 118(21):2771.
36. Marin D., Milojkovic D., Olavarria E., Khorashad J.S., de Lavallade H., Reid A.G., et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112(12):4437-4444.
37. Alvarado Y., Kantarjian H., O'Brien S., Faderl S., Borthakur G., Burger J., et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115(16):3709-3718.
38. Quintás-Cardama A., Kantarjian H., Jones D., Shan J., Borthakur G., Thomas D., et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009, 113(25):6315-6321.
39. Hughes T.P., Hochhaus A., Branford S., Muller M.C., Kaeda J.S., Foroni L., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116(19):3758-3765.
40. Hehlmann R., Lauseker M., Jung-Munkwitz S., Leitner A., Müller M.C., Pletsch N., et al. Tolerability-adapted imatinib 800mg/d versus 400mg/d versus 400mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011, 29(12):1634-1642.
41. Marin D., Ibrahim A.R., Lucas C., Gerrard G., Wang L., Szydlo R.M., et al. Assessment of BCR-ABL1 transcript levels at 3months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30(3):232-238.
42. Saglio G., Hochhaus A., Guilhot F., Gattermann N., Wang M.-C., De Souza C., et al. Nilotinib is associated with fewer treatment failures and suboptimal responses vs imatinib in patients with newly diagnosed chronic myeloid leukemia chronic phase (CML-CP): results from ENESTnd. Haematologica 2011, 96(Suppl. 2):58-59.
43. Noens L., van Lierde M.A., De Bock R., Verhoef G., Zachee P., Berneman Z., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113(22):5401-5411.
44. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353(5):487-497.
45. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 2002, 54(2):212-220.
46. Marin D., Bazeos A., Mahon F.X., Eliasson L., Milojkovic D., Bua M., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010, 28(14):2381-2388.
47. Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood 2011, 117(14):3733-3736.
48. Darkow T., Henk H.J., Thomas S.K., Feng W., Baladi J.F., Goldberg G.A., et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007, 25(6):481-496.
49. Wu E.Q., Johnson S., Beaulieu N., Arana M., Bollu V., Guo A., et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010, 26(1):61-69.
50. O'Dwyer M., Atallah E. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol 2009, 46(2 (Suppl. 3)):S16-21.
51. Jabbour E., Deininger M., Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011, 25(2):201-210.
52. Guilhot F., Coombs J., Zernovak O., Szczudlo T., Rosti G. A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). ASH Annual Meeting Abstr 2010, 116(21):1514.
53. Eliasson L., Clifford S., Barber N., Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011, 35(5):626-630.
54. Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
55. St.Charles M., Bollu V.K., Hornyak E., Coombs J., Blanchette C.M., DeAngelo D.J. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. ASH Annual Meeting Abstr 2009, 114(22):2209.
56. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109(6):2303-2309.
57. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110(10):3540-3546.
58. Shah N.P., Kantarjian H.M., Kim D.W., Rea D., Dorlhiac-Llacer P.E., Milone J.H., et al. Intermittent target inhibition with dasatinib 100mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26(19):3204-3212.
59. Ramirez P., DiPersio J.F. Therapy options in imatinib failures. Oncologist 2008, 13(4):424-434.
60. ClinicalTrials.gov. NCT01220648. Determining the maximum tolerated dose of low dose interferon-alfa in conjunction with nilotinib in imatinib resistant and/or intolerant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia patients in chronic phase (CML-CP) (NICOLI). <>; 2010 [accessed 14.11.2011]. http://www.clinicaltrials.gov/ct2/show/NCT01220648?term=NCT01220648&rank=1.
61. ClinicalTrials.gov. NCT00866736. A study of dasatinib in patients with imatinib resistant or intolerant chronic myeloid leukemia.
62. ClinicalTrials.gov. NCT01426334. Dasatinib and cyclosporine in treating patients with chronic myelogenous leukemia refractory or intolerant to imatinib mesylate. <>; 2011 [accessed 17.01.2012]. http://www.clinicaltrials.gov/ct2/show/NCT01426334?term=NCT01426334&rank=1.
63. ClinicalTrials.gov. NCT00786812. Study of treatment with nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase (ENACT). <>; 2008 [accessed 17.01.2012]. http://www.clinicaltrials.gov/ct2/show/NCT00786812?term=NCT00786812&rank=1.
64. ClinicalTrials.gov. NCT00538109. An open-label, multicenter, expanded access study of oral AMN 107 in adult patients with imatinib (Glivec®/Gleevec®) - resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase. <>; 2007 [accessed 17.01.2012]. http://www.clinicaltrials.gov/ct2/show/NCT00538109?term=NCT00538109&rank=1.
65. ClinicalTrials.gov. NCT00777036. A phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase CML or with Ph+ leukemias resistant or intolerant to imatinib. <>; 2008 [accessed 14.11.2011]. http://www.clinicaltrials.gov/ct2/show/NCT00777036?term=NCT00777036&rank=1.
66. ClinicalTrials.gov. NCT00980018. An exploratory trial to assess the improvement of adverse events in chronic myelogenous leukemia patients treated with imatinib when switched to nilotinib treatment. <>; 2009 [accessed 17.01.2012]. http://www.clinicaltrials.gov/ct2/show/NCT00980018?term=NCT00980018&rank=1.
67. Khoury H.J., Goldberg S.L., Mauro M.J., Stone R.M., Matloub Y., Chen T., et al. Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety. J Clin Oncol 2008, 26(Suppl.):7015.
68. Kobayashi Y., Sakamaki H., Fujisawa S., Ando K., Yamamoto K., Okada M., et al. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Int J Hematol 2011, 93(6):745-749.
69. Cortes J.E., Hochhaus A., le Coutre P.D., Rosti G., Pinilla-Ibarz J., Jabbour E., et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 2011, 117(21):5600-5606.
70. Cortes J.E., Miller C.B., Lipton J.H., Busque L., Akard L.P., Pinilla-Ibarz J., et al. Open-label study evaluating change in chronic low-grade (LG) non-hematologic (heme) adverse events (AEs) in Philadelphia positive (Ph+) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). J Clin Oncol 2011, 29(Suppl.):6615.
71. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance. 24-month follow-up results. Blood 2011, 117(4):1141-1145.
72. Quintas-Cardama A., Cortes J.E., O'Brien S., Ravandi F., Borthakur G., Liu D., et al. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115(13):2912-2921.
73. Eghtedar A., Kantarjian H., Jabbour E., O'Brien S., Quintas-Cardama A., Burton E., et al. Outcome after failure to second generation tyrosine kinase inhibitors (TKI) treatment as frontline therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CP). ASH Annual Meeting Abstr 2010, 116(21):3442.
74. Tauchi T., Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004, 28(Suppl. 1):S39-45.
75. Bixby D., Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009, 23:461-476.
76. Jabbour E., Jones D., Kantarjian H.M., O'Brien S., Tam C., Koller C., et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009, 114(10):2037-2043.
77. Soverini S., Martinelli G., Rosti G., Bassi S., Amabile M., Poerio A., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005, 23(18):4100-4109.
78. Soverini S., Hochhaus A., Nicolini F.E., Gruber F., Lange T., Saglio G., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011, 118(5):1208-1215.
79. Corbin A.S., La Rosee P., Stoffregen E.P., Druker B.J., Deininger M.W. Several BCR-ABL kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003, 101(11):4611-4614.
80. Saglio G., Kantarjian H., Reiffers J., Jootar S., Kalaycio M.E., Shibayama H., et al. The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up. J Clin Oncol 2011, 29(Suppl.):6502.
81. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682):399-401.
82. Jabbour E., Kantarjian H.M., Jones D., Reddy N., O'Brien S., Garcia-Manero G., et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008, 112(13):4839-4842.
83. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of BCR-ABL inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant ABL kinase domain mutants. Cancer Res 2005, 65(11):4500-4505.
84. Weisberg E., Manley P., Mestan J., Cowan-Jacob S., Ray A., Griffin J.D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94(12):1765-1769.
85. Hughes T., Saglio G., Branford S., Soverini S., Kim D.-W., Müller M.C., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009, 27(25):4204-4210.
86. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531):876-880.
87. Jabbour E., Kantarjian H., Jones D., Breeden M., Garcia-Manero G., O'Brien S., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008, 112(1):53-55.
88. Mauro M.J. Defining and managing imatinib resistance. Hematology 2006, 2006(1):219-225.
89. Zhou T., Commodore L., Huang W.S., Wang Y., Thomas M., Keats J., et al. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011, 77(1):1-11.
90. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5):401-412.
91. Cortes JE, Kantarjian HM, Shah N, Bixby D, Mauro MJ, Flinn IW, et al. Subset analysis of response to treatment of chronic phase cml in a phase 1 study of ponatinib in refractory hematologic malignancies. Presented at: 53rd ASH Annual Meeting and Exposition, December 12, 2011; San Diego, CA. Abstract 602.
92. Eide C.A., Adrian L.T., Tyner J.W., Mac Partlin M., Anderson D.J., Wise S.C., et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res 2011, 71(9):3189-3195.
93. Cortes JE, Talpaz M, Kantarjian HM, Smith H, Bixby D, Rafferty U, et al. A phase 1 study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. Presented at: 53rd ASH Annual Meeting and Exposition, December 12, 2011, San Diego, CA. Abstract 601.
94. Gontarewicz A., Balabanov S., Keller G., Colombo R., Graziano A., Pesenti E., et al. Simultaneous targeting of Aurora kinases and BCR-ABL kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008, 111(8):4355-4364.
95. Cortes-Franco J., Dombret H., Schafhausen P., Brummendorf T.H., Boissel N., Latini F., et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114:864.
96. Quintas-Cardama A., Kantarjian H., Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009, 115(23):5382-5393.
97. Chen Y., Hu Y., Michaels S., Segal D., Brown D., Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009, 23(8):1446-1454.
98. Cortes J.E., Nicolini F.E., Wetzler M., Lipton J.H., Akard L.P., Craig A., et al. Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib. Blood (ASH Annual Meeting Abstracts) 2011, 118:3761.